Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
about
The role of angiogenesis in prostate and other urologic cancers: a review.Interferon alpha for the treatment of advanced renal cancer.Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II studyImmunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialEvaluation of the diagnostic utility of endobronchial ultrasound-guided transbronchial needle aspiration for metastatic mediastinal tumors.Expression and proliferation-promoting role of lymphoid enhancer-binding factor 1 in human clear cell renal carcinoma.Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.Synchronous pulmonary metastases from renal cell carcinoma--a whole nation study on prevalence and potential resectability.Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
P2860
Q33955367-289ED5C5-46AE-4075-ACE8-3AD8994A3ABAQ36161207-1B6B61D5-08D0-4B96-B0E1-91E018112C9FQ36348109-7F82E0FA-B455-4428-ABEE-99E715416932Q36621976-1034D4F2-FDB1-418C-B4BD-65EBCF49CA89Q36641423-9F615A4E-9876-4217-8269-DA2FC45FB68CQ36673573-A8DCF0E3-BB7B-4139-ABBA-FF609360B203Q37031788-E77FF41A-AD03-43CE-8778-F9E87B814309Q38988373-9EA1292F-A3B1-4C43-82CA-02B799148560Q40516413-CFB798F5-1A7B-4019-884E-DF4F8E07902FQ40576877-D48D441A-8C01-483A-8CA3-1047F205AB6AQ44046746-BFC78EEA-BC8C-4112-84B7-A0A4A82773D7Q44124135-32814D14-E3DB-4776-8066-725438F7A7B6Q44168587-E9F8B0C9-9673-4666-B9DD-80D0D736F7CD
P2860
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@en
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@nl
type
label
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@en
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@nl
prefLabel
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@en
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@nl
P2093
P1476
Subcutaneous interleukin-2, in ...... upe Français d'Immunothérapie.
@en
P2093
B Escudier
C Chevreau
C Linassier
J M Ferrero
J Y Douillard
L Geoffrois
P304
P356
10.1200/JCO.1998.16.8.2728
P407
P577
1998-08-01T00:00:00Z